Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CN54ENV DNA vaccine + interleukin-12 plasmid DNA
- Development stage
- Unknown
- Lead developer
- Imperial College London
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Intradermal
01
Overview
CN54ENV is an HIV-1 DNA vaccine candidate developed by Ichor Medical Systems in collaboration with Imperial College London. The vaccine consists of a DNA plasmid encoding the HIV-1 envelope glycoprotein (gp140) derived from the 97CN54 clade C isolate. It is designed to be delivered via intramuscular or intradermal electroporation using Ichor's TriGrid Delivery System (TDS-IM) to enhance cellular uptake and immunogenicity. In clinical study regimens, the vaccine may be co-administered with an interleukin-12 (IL-12) plasmid DNA adjuvant to further boost immune responses and may include a subsequent protein boost with recombinant CN54gp140. The primary goal is to elicit both humoral and cellular immune responses against the HIV envelope protein.
- Other names
- CN54ENV DNA vaccineCN-54ENV DNA vaccineCN 54ENV DNA vaccineCN54ENV DNA vaccine + IL-12 plasmid DNACN54ENV DNA vaccine + interleukin-12 plasmid DNA-Ichor Systems
02
Targets
gp140 (HIV-1 gp140)
Beyond the preview
Go deeper on CN54ENV DNA vaccine + interleukin-12 plasmid DNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CN54ENV DNA vaccine + interleukin-12 plasmid DNA.